Beyond GLP-1: The Next Generation of Weight Loss Drugs in the Pipeline
GLP-1 receptor agonists have dominated the obesity conversation since 2021. But the next wave of weight loss drugs is taking fundamentally different approaches — some dropping GLP-1 targeting entirely.
The "No GLP-1 Needed" Hypothesis
In April 2026, a team led by Richard DiMarchi and Matthias Tschöp — the scientists whose work enabled tirzepatide's development — published a provocative finding: a drug that activates only GIP and glucagon receptors (no GLP-1) produced weight loss comparable to existing GLP-1 drugs in rodent and monkey studies.
The potential advantage? GLP-1 receptor activation is responsible for much of the nausea and vomiting that limits how aggressively current drugs can be dosed. If you can achieve similar weight loss through different receptor pathways, you might avoid the tolerability ceiling that prevents many patients from reaching maximum doses.
In monkey studies, animals given high doses of the new compound showed no signs of distress, while those given existing GLP-1 drugs could not tolerate higher doses.
Pipeline Drugs to Watch
| Drug | Company | Mechanism | Stage | What's Different |
|---|---|---|---|---|
| MariTide | Amgen | GLP-1/GIP dual agonist + anti-GIPR antibody | Phase 3 | Monthly injection (vs. weekly). Strong early weight loss data. |
| VK2735 | Viking Therapeutics | GLP-1/GIP dual agonist | Phase 2/3 | Both injectable and oral forms in development. Oral showed ~7% weight loss at 28 days. |
| Retatrutide | Eli Lilly | Triple agonist (GLP-1/GIP/glucagon) | Phase 3 | Up to 24% weight loss in Phase 2. The most effective single agent tested to date. |
| Survodutide | Boehringer Ingelheim / Zealand | GLP-1/glucagon dual agonist | Phase 3 | Strong liver fat reduction — potential for MASH indication. |
| CagriSema | Novo Nordisk | Semaglutide + amylin analog | Phase 3 | Combining two mechanisms for enhanced weight loss vs. semaglutide alone. |
| GIP/Glucagon (unnamed) | BlueWater Biosciences | GIP/glucagon dual agonist (no GLP-1) | Preclinical | Potentially avoids GLP-1-driven nausea entirely. |
What This Means for Patients Today
Don't wait for the pipeline. The drugs above are 2-5 years from potential approval. If you need treatment now, current options are effective and well-characterized.
Current options keep improving. Foundayo just launched. Wegovy pill just launched. Zepbound keeps getting price cuts. The market you're in today is already dramatically better than 12 months ago.
Watch for combo approaches. CagriSema and retatrutide represent the trend toward hitting multiple pathways simultaneously. The future of obesity treatment is likely multi-mechanism, personalized, and increasingly oral.